Brief: Premas Biotech Secures Licensing Deal For Commercializing Its Vaccine Technology In India
03/08/2021 10:29
Aug 3 (Reuters) - Premas Biotech:
* SIGNS LICENSING DEAL FOR VIRUS-LIKE PARTICLE INJECTABLE
VACCINE
TECHNOLOGY FOR COVID-19, WITH ORAVAX FOR COMMERCIALIZATION IN
INDIA
* VLP VACCINE BEING TESTED AGAINST COVID-19 VARIANTS
INCLUDING
DELTA
Further company coverage: ORMP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oramed Pharmaceuticals
See all newsBrief: Nano Dimension Appoints Nadav Kidron To Board Of Directors To Chair Strategy And Capital Allocation Committee
Oramed Pharmaceuticals Inc expected to post earnings of 43 cents a share - Earnings Preview
Brief: Oramed And Lifeward Announce Strategic Transaction
Brief: Oramed Receives $18 Million Payment From Scilex Holdings
Brief: Oramed Reports Fiscal Third Quarter 2025 Financial Results